Sandoz

Novartis chief Vas Narasimhan wants you to know about the '25-plus’ blockbusters he has in the pipeline
Novartis chief Vas Narasimhan wants you to know about the '25-plus’ blockbusters he has in the pipeline
Endpoints
Novartis
R&D
Sandoz
Pharma CEOs
Vas Narasimhan
Flag link:
Novartis' Sandoz does digital from back office to 'not just apps' therapeutics
Novartis' Sandoz does digital from back office to 'not just apps' therapeutics
Fierce Pharma
digital pharma
Sandoz
Novartis
Flag link:
Novartis vows to fight U.S. price-fixing claims against Sandoz unit
Novartis vows to fight U.S. price-fixing claims against Sandoz unit
Yahoo/Reuters
Novartis
Sandoz
generics
price fixing
Flag link:
Novartis Poaches GSK Veteran as New Sandoz CEO
Novartis Poaches GSK Veteran as New Sandoz CEO
BioSpace
Novartis
Sandoz
generics
Pharma CEOs
Richard Saynor
GSK
Flag link:
United Therapeutics Fires Back After Sandoz Files Anti-Competitive Lawsuit Over PAH Drug
United Therapeutics Fires Back After Sandoz Files Anti-Competitive Lawsuit Over PAH Drug
BioSpace
United Therapeutics
PAH
Remodulin
generics
Sandoz
Flag link:
Sandoz resubmission puts Amgen's Neulasta at further risk of competition
Sandoz resubmission puts Amgen's Neulasta at further risk of competition
Biopharma Dive
FDA
Novartis
biosimilars
Sandoz
Amgen
Neulasta
Flag link:
CEO of Novartis’ generics unit quits, sparking sale speculation
CEO of Novartis’ generics unit quits, sparking sale speculation
Pharmaforum
Novartis
Sandoz
generics
M&A
Richard Francis
biosimilars
Flag link:
Indivior introduces generic version of Suboxone opioid drug in US
Indivior introduces generic version of Suboxone opioid drug in US
Pharmaceutical Business Review
Indivior
Sandoz
generics
opioids
Suboxone Film
Flag link:
‘De-intergration’ of Sandoz from Novartis expected to include manufacturing cuts
‘De-intergration’ of Sandoz from Novartis expected to include manufacturing cuts
Fierce Pharma
Novartis
Sandoz
layoffs
drug manufacturing
Flag link:
Novartis plots new course for Sandoz
Novartis plots new course for Sandoz
BioCentury
Novartis
Sandoz
generics
Flag link:
UnitedHealthcare, fueled by federal probes, sues generics makers for price fixing
UnitedHealthcare, fueled by federal probes, sues generics makers for price fixing
Fierce Pharma
UnitedHealthcare
generics
price fixing
drug pricing
Mylan
Teva Pharmaceuticals
Sandoz
Actavis
Par Pharmaceutical
Sun Pharma
Aurobindo
Taro Pharmaceuticals
Flag link:
Sandoz launches EpiPen rival at $250 per two-pack
Sandoz launches EpiPen rival at $250 per two-pack
BioPharma Dive
Sandoz
Novartis
EpiPens
Symjepi
Flag link:
Adamis stock surges on release of EpiPen alternative
Adamis stock surges on release of EpiPen alternative
Marketwatch
Adamis
Mylan
Sandoz
EpiPens
Symjepi
Flag link:
Novartis unit teams up with medical marijuana producer, marking milestone for pharma
Novartis unit teams up with medical marijuana producer, marking milestone for pharma
Stat
Novartis
Sandoz
Medical Marijuana
Tilray Canada
Flag link:
Sandoz prepares early 2019 launch for EpiPen alternative Symjepi at 16% discount
Sandoz prepares early 2019 launch for EpiPen alternative Symjepi at 16% discount
Fierce Pharma
Novartis
Sandoz
generics
Symjepi
EpiPens
Teva Pharmaceutical
Mylan
Flag link:
Pear, Sandoz launch first FDA-approved digital therapeutic
Pear, Sandoz launch first FDA-approved digital therapeutic
BioCentury
Pear Therapeutics
Sandoz
digital therapeutics
substance abuse
reSET
Flag link:
Novartis 'completely committed' to Sandoz, has no split-off plan
Novartis 'completely committed' to Sandoz, has no split-off plan
Yahoo/Reuters
Novartis
Sandoz
generics
Flag link:
Novartis' Sandoz calls it quits on Rituxan biosimilar after FDA requests more data
Novartis' Sandoz calls it quits on Rituxan biosimilar after FDA requests more data
Fierce Pharma
Novartis
Sandoz
FDA
biosimilars
Roche
Rituxan
Flag link:
Novartis abandons effort for U.S. approval of biosimilar rituximab
Novartis abandons effort for U.S. approval of biosimilar rituximab
Yahoo/Reuters
Novartis
Sandoz
rituximab
biosimilars
Roche
Flag link:
Battle Over Humira Begins in Europe as 5-Year Wait Begins in US
Battle Over Humira Begins in Europe as 5-Year Wait Begins in US
RAPS.org
Europe
AbbVie
Humira
Amgen
Samsung Bioepis
Mylan Labs
Novartis
Sandoz
Fresenius Kabi
Boehringer Ingelheim
Flag link:

Pages